Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Peptides are at the cutting edge of contemporary research for new potent, selective, and safe therapeutical agents. Their rise has reshaped the pharmaceutical landscape, providing solutions to challenges that traditional small molecules often cannot address. A wide variety of natural and modified peptides have been obtained and studied, and many others are advancing in clinical trials, covering multiple therapeutic areas. As the demand for peptide-based therapies grows, so does the need for sustainable and environmentally friendly synthesis methods. Traditional peptide synthesis, while effective, often involves environmentally draining processes, generating significant waste and consuming vast resources. The integration of green chemistry offers sustainable alternatives, prioritizing eco-friendly processes, waste reduction, and energy conservation. This review delves into the transformative potential of applying green chemistry principles to peptide synthesis by discussing relevant examples of the application of such approaches to the production of active pharmaceutical ingredients (APIs) with a peptide structure and how these efforts are critical for an effective green transition era in the pharmaceutical field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 2×
“Decades later, the improvement of peptide solid phase synthesis, the development of recombinant technologies, and the discovery of new peptides from natural sources stimulated the scientific world toward the development of peptides as therapeutic agents [1–3].”
BackgroundInfluentialDemographic and epidemiologic drivers of global cardiovascular mortality
Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406656 · Cited by 1,188 · cited 2×
“…for CVDs is an urgent need, as it is estimated that between 1990 and 2013 the number of deaths caused by these pathologies increased by about 40% due to population growth and aging [95]. levels of low-density lipoprotein (LDL) cholesterol are one of the major causes that HDL deficiency [99].”
BackgroundStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · cited 2×
“…in various tumor forms, in the last years, RGD-based antagonists found a second life as drug delivery systems [78–80]. drug against glioblastoma has been discontinued due to failure in phase-III clinical trials, and consequently, the use of integrin antagonists has been set aside for a while [77].”
BackgroundEnvironmental antimicrobial resistance and its drivers: a potential threat to public health
Samreen, Ahmad, I., Malak, H. A., & Abulreesh, H. H. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.08.001 · Cited by 727 · cited 2×
“The rise of AMR poses a significant threat to global health, with projections indicating that, by 2050, infections complicated by AMR could result in the death of 10 million people annually [23,24].”
BackgroundSubirós‐Funosas, R., Prohens, R., Barbas, R., El‐Faham, A., & Albericio, F. (2009) · Chemistry – A European Journal · doi:10.1002/chem.200900614 · Cited by 421 · cited 1×
“The ethyl cyano(hydroxyimino)acetate, known as OxymaPure ® (Figure 21), hereafter just Oxyma, and the corresponding potassium salt K-Oxyma were first proposed in 2009 by Albericio’s team as effective epimerization-suppressing additives [132].”
Method100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270 · cited 1×
“Decades later, the improvement of peptide solid phase synthesis, the development of recombinant technologies, and the discovery of new peptides from natural sources stimulated the scientific world toward the development of peptides as therapeutic agents [1–3].”
BackgroundThe greening of peptide synthesis
Lawrenson, S. B., Arav, R., & North, M. (2017) · Green Chemistry · doi:10.1039/c7gc00247e · Cited by 205
Viral Infections, the Microbiome, and Probiotics
Harper, A., Vijayakumar, V., Ouwehand, A. C., ter Haar, J., Obis, D., Espadaler, J., Binda, S., Desiraju, S., & Day, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.596166 · Cited by 177 · cited 1×
“Together with vaccines, antiviral drugs play a relevant role in fighting this kind of illness [33–35].”
BackgroundMarked HDL deficiency and premature coronary heart disease
Schaefer, E. J., Santos, R. D., & Asztalos, B. F. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1ef6 · Cited by 127
Peptide synthesis beyond DMF: THF and ACN as excellent and friendlier alternatives
Jad, Y. E., Acosta, G. A., Khattab, S. N., de la Torre, B. G., Govender, T., Kruger, H. G., El-Faham, A., & Albericio, F. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02046d · Cited by 92
Solid‐phase peptide synthesis using acetonitrile as a solvent in combination with PEG‐based resins
Acosta, G. A., del Fresno, M., Paradis‐Bas, M., Rigau‐DeLlobet, M., Côté, S., Royo, M., & Albericio, F. (2009) · Journal of Peptide Science · doi:10.1002/psc.1158 · Cited by 63 · cited 2×
“Albericio and coworkers proposed the use of acetonitrile (ACN) and tetrahydrofuran (THF) as alternatives to DMF and NMP in SPPS, in combination with PEG-based resins [116].”
MethodHojo, K., Shinozaki, N., Hidaka, K., Tsuda, Y., Fukumori, Y., Ichikawa, H., & Wade, J. D. (2014) · Amino Acids · doi:10.1007/s00726-014-1779-y · Cited by 34 · cited 1×
“Afterwards, the same group reported an aqueous microwave peptide synthesis, which showed promising applicability in the preparation of racemization-sensitive derivatives, such as histidine-containing peptides [124].”
Background
Cited by
Dermawan, D., & Alotaiq, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-93683-1 · Cited by 19
Murail, S., Sawmynaden, J., Zemirli, A., Jusot, M., Pietrucci, F., Chomilier, J., Tufféry, P., & Stratmann, D. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c01123 · Cited by 6
Metadata
- Authors
- Rossino, G., Marchese, E., Galli, G., Verde, F., Finizio, M., Serra, M., Linciano, P., & Collina, S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2023-10-19
- Volume
- 28
- Issue
- 20
- Pages
- 7165
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4387776183
- Cited by
- 235
- References
- 13
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.